Compare OPAL & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | XBIT |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Pharmaceuticals and Biotechnology |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 74.4M |
| IPO Year | 2021 | 2015 |
| Metric | OPAL | XBIT |
|---|---|---|
| Price | $2.21 | $2.33 |
| Analyst Decision | Sell | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.72 | N/A |
| AVG Volume (30 Days) | ★ 350.0K | 25.9K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $2.09 |
| 52 Week High | $2.87 | $3.61 |
| Indicator | OPAL | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 44.55 |
| Support Level | $2.01 | $2.26 |
| Resistance Level | $2.37 | $2.49 |
| Average True Range (ATR) | 0.15 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 62.50 | 30.00 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.